Ensysce Biosciences, Inc. (ENSC)

Over the past six months, Ensysce Biosciences' stock has shown volatility and a downward trend, with a share price of $0.46 as of February 5, 2026. Key events include Q2 2025 financial results and the launch of a Phase 3 clinical trial for PF614. In November 2025, they secured $4.0 million in convertible preferred financing and received positive FDA feedback. December 2025 saw the initiation of enrollment for the pivotal Phase 3 trial of PF614 and broader patent protection for MPAR® technology. In January 2026, the company issued its 2025 annual shareholder letter and expanded its global opioid patent portfolio. Despite positive announcements, the stock has often experienced negative price reactions.

Ensysce Biosciences' products are not subject to traditional consumer demand seasonality. Demand for its pipeline products will be driven by medical need, regulatory approvals, and market adoption within the healthcare system.

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing safer prescription drugs for opioid abuse and central nervous system disorders. They utilize the TAAP™ platform to create abuse-resistant opioid prodrugs and the MPAR® platform to reduce overdose potential. Their lead candidate is PF614, an extended-release oxycodone analgesic in Phase 3 trials. They are also developing PF8026 for ADHD and PF9001 for opioid use disorder.

Ensysce Biosciences is headquartered in La Jolla, California. They have expanded global intellectual property protection, including a recent patent in Brazil. Clinical trials are conducted across multiple U.S. sites, including Salt Lake City, Utah; Decatur, Georgia; and Houston, Texas.

Ensysce Biosciences aims to build a reputation as an innovative biotech company addressing prescription drug abuse. Positive FDA designations have been received. However, the market's reaction to company news has often been bearish, potentially impacting the company's brand reputation among investors. The company actively communicates its progress to reinforce its mission and advancements.

Ensysce Biosciences has 18 institutional owners and shareholders holding a total of 351,686 shares. Institutional investors own approximately 0.44% of the company's stock, insiders own 0.62%, and public companies and individual investors own 98.94%. Major institutional shareholders include Perceptive Advisors Llc and Adage Capital Partners Gp, L.l.c.. Joseph Edelman owns the most shares among individual investors.